A technique that checks the first lymph node likely to harbour hidden cancer spread is helping doctors decide who actually needs extensive surgery and who can safely avoid it ...
FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results